PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis.

Science translational medicine, Volume: 6, Issue: 265
December 3, 2014
M Teresa Coleman MT, Ray Y Chen RY, Myungsun Lee M, Philana Ling Lin PL, Lori E Dodd LE, Pauline Maiello P, Laura E Via LE, Youngran Kim Y, Gwendolyn Marriner G, Veronique Dartois V, Charles Scanga C, Christopher Janssen C, Jing Wang J, Edwin Klein E, Sang Nae Cho SN, Clifton E Barry CE, JoAnne L Flynn JL

Oxazolidinone antibiotics such as linezolid have shown significant therapeutic effects in patients with extensively drug-resistant (XDR) tuberculosis (TB) despite modest effects in rodents and no demonstrable early bactericidal activity in human phase 2 trials. We show that monotherapy with either linezolid or AZD5847, a second-generation oxazolidinone, reduced bacterial load at necropsy in Mycobacterium tuberculosis-infected cynomolgus macaques with active TB. This effect coincided with a decline in 2-deoxy-2-[(18)F]-fluoro-d-glucose positron emission tomography (FDG PET) imaging avidity in the lungs of these animals and with reductions in pulmonary pathology measured by serial computed tomography (CT) scans over 2 months of monotherapy. In a parallel phase 2 clinical study of linezolid in patients infected with XDR-TB, we also collected PET/CT imaging data from subjects receiving linezolid that had been added to their failing treatment regimens. Quantitative comparisons of PET/CT imaging changes in these human subjects were similar in magnitude to those observed in macaques, demonstrating that the therapeutic effect of these oxazolidinones can be reproduced in this model of experimental chemotherapy. PET/CT imaging may be useful as an early quantitative measure of drug efficacy against TB in human patients.

Courtesy of the U.S. National Library of Medicine